The Creatine Paradox

From Clinical Evidence to Consumer Claims

Creatine is increasingly marketed for memory, mood and cognitive health. This three-part investigation follows those claims from the studies behind them to regulatory review, psychiatric trial exclusions and the commercial relationships surrounding the research, examining what changes as clinical evidence moves into consumer marketing.

Close-up of a scientific research paper with the phrase "in vegetarians" circled in red ink, highlighting the specific demographic used in cognitive studies.
  • 01

The Creatine Vegetarian Gap – From Scientific Research to Marketing Claims

Early creatine trials reported cognitive benefits, but later studies produced mixed or null results. In 2024, UK and EU regulators found the evidence insufficient for the proposed health claim.

A forensic still life of an investigator's desk featuring a clinical trial protocol with the text 'Exclusion Criteria: History of Mania, Bipolar I Disorder' circled in red, placed next to a commercial tub of creatine supplement labeled 'Mood & Focus Support'.
  • 02

Creatine and Bipolar Risk – The Clinical Trials and Consumer Marketing Gap

Creatine trials have recorded manic or hypomanic switching in bipolar patients, while later studies excluded bipolar disorder or wider psychiatric conditions. This investigation compares that clinical record with the mood and brain-health claims used in consumer marketing.

A high-angle shot of a dimly lit desk scattered with academic papers. A hand holding a pen has circled a footnote in a document that reads 'Conflict of Interest: Author declares financial ties to AlzChem Trostberg GmbH,' illustrating the centralised funding of creatine research.
  • 03

Creatine Cognitive Research – Academic Disclosures and Consumer Marketing

Researchers disclosed financial ties to creatine manufacturers and supplement brands in academic papers. Those disclosures are not fully reproduced on reviewed consumer pages carrying cognitive claims.

Back To Top